Is BOLT or CRIS more profitable?

Curis has a net margin of -80.29% compared to Bolt Biotherapeutics' net margin of -455.15%. Curis' return on equity of 0.00% beat Bolt Biotherapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Bolt Biotherapeutics -455.15% -100.89% -48.23% Curis -80.29% N/A -181.57%

Does the media favor BOLT or CRIS?

In the previous week, Bolt Biotherapeutics had 6 more articles in the media than Curis. MarketBeat recorded 8 mentions for Bolt Biotherapeutics and 2 mentions for Curis. Curis' average media sentiment score of 1.87 beat Bolt Biotherapeutics' score of -0.47 indicating that Curis is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bolt Biotherapeutics 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Curis 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Is BOLT or AMGN more profitable?

Amgen has a net margin of 20.96% compared to Bolt Biotherapeutics' net margin of -455.15%. Amgen's return on equity of 137.41% beat Bolt Biotherapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Bolt Biotherapeutics -455.15% -100.89% -48.23% Amgen 20.96% 137.41% 13.28%

Does the media favor BOLT or AMGN?

In the previous week, Amgen had 26 more articles in the media than Bolt Biotherapeutics. MarketBeat recorded 34 mentions for Amgen and 8 mentions for Bolt Biotherapeutics. Amgen's average media sentiment score of 1.06 beat Bolt Biotherapeutics' score of -0.47 indicating that Amgen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bolt Biotherapeutics 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Amgen 23 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 2 Very Negative mention(s) Positive

Does the media favor GILD or BOLT?

In the previous week, Gilead Sciences had 38 more articles in the media than Bolt Biotherapeutics. MarketBeat recorded 46 mentions for Gilead Sciences and 8 mentions for Bolt Biotherapeutics. Gilead Sciences' average media sentiment score of 1.41 beat Bolt Biotherapeutics' score of -0.47 indicating that Gilead Sciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Gilead Sciences 36 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive Bolt Biotherapeutics 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor VRTX or BOLT?

In the previous week, Vertex Pharmaceuticals had 30 more articles in the media than Bolt Biotherapeutics. MarketBeat recorded 38 mentions for Vertex Pharmaceuticals and 8 mentions for Bolt Biotherapeutics. Vertex Pharmaceuticals' average media sentiment score of 1.19 beat Bolt Biotherapeutics' score of -0.47 indicating that Vertex Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vertex Pharmaceuticals 29 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Bolt Biotherapeutics 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor REGN or BOLT?

In the previous week, Regeneron Pharmaceuticals had 19 more articles in the media than Bolt Biotherapeutics. MarketBeat recorded 27 mentions for Regeneron Pharmaceuticals and 8 mentions for Bolt Biotherapeutics. Regeneron Pharmaceuticals' average media sentiment score of 0.68 beat Bolt Biotherapeutics' score of -0.47 indicating that Regeneron Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Regeneron Pharmaceuticals 12 Very Positive mention(s) 3 Positive mention(s) 9 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive Bolt Biotherapeutics 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Bolt Biotherapeutics (BOLT) Competitors

$5.19 +0.08 (+1.57%)

As of 10:08 AM Eastern

Compare

BOLT vs. CRIS, AMGN, GILD, VRTX, and REGN

Should you buy Bolt Biotherapeutics stock or one of its competitors? MarketBeat compares Bolt Biotherapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Bolt Biotherapeutics include Curis (CRIS), Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), and Regeneron Pharmaceuticals (REGN). These companies are all part of the "biotechnology" industry.

How does Bolt Biotherapeutics compare to Curis?

Bolt Biotherapeutics (NASDAQ:BOLT) and Curis (NASDAQ:CRIS) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, profitability, valuation, institutional ownership, analyst recommendations, earnings, risk and dividends.

86.7% of Bolt Biotherapeutics shares are owned by institutional investors. Comparatively, 30.0% of Curis shares are owned by institutional investors. 9.4% of Bolt Biotherapeutics shares are owned by insiders. Comparatively, 5.4% of Curis shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Curis has lower revenue, but higher earnings than Bolt Biotherapeutics. Curis is trading at a lower price-to-earnings ratio than Bolt Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bolt Biotherapeutics	$7.70M	1.29	-$33.38M	-$16.33	N/A
Curis	$7.06M	2.79	-$7.58M	-$1.19	N/A

In the previous week, Bolt Biotherapeutics had 6 more articles in the media than Curis. MarketBeat recorded 8 mentions for Bolt Biotherapeutics and 2 mentions for Curis. Curis' average media sentiment score of 1.87 beat Bolt Biotherapeutics' score of -0.47 indicating that Curis is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bolt Biotherapeutics	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Curis	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Bolt Biotherapeutics has a beta of 1.12, indicating that its share price is 12% more volatile than the broader market. Comparatively, Curis has a beta of 3.05, indicating that its share price is 205% more volatile than the broader market.

Curis has a net margin of -80.29% compared to Bolt Biotherapeutics' net margin of -455.15%. Curis' return on equity of 0.00% beat Bolt Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bolt Biotherapeutics	-455.15%	-100.89%	-48.23%
Curis	-80.29%	N/A	-181.57%

Bolt Biotherapeutics currently has a consensus price target of $34.67, suggesting a potential upside of 567.95%. Curis has a consensus price target of $17.00, suggesting a potential upside of 3,259.02%. Given Curis' higher possible upside, analysts clearly believe Curis is more favorable than Bolt Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bolt Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Curis	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.67

Summary

Bolt Biotherapeutics and Curis tied by winning 8 of the 16 factors compared between the two stocks.

How does Bolt Biotherapeutics compare to Amgen?

Bolt Biotherapeutics (NASDAQ:BOLT) and Amgen (NASDAQ:AMGN) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, dividends, earnings, media sentiment, risk and profitability.

Amgen has higher revenue and earnings than Bolt Biotherapeutics. Bolt Biotherapeutics is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bolt Biotherapeutics	$7.70M	1.29	-$33.38M	-$16.33	N/A
Amgen	$36.75B	4.86	$7.71B	$14.37	23.02

Bolt Biotherapeutics presently has a consensus target price of $34.67, suggesting a potential upside of 567.95%. Amgen has a consensus target price of $355.19, suggesting a potential upside of 7.39%. Given Bolt Biotherapeutics' higher probable upside, analysts plainly believe Bolt Biotherapeutics is more favorable than Amgen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bolt Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Amgen	2 Sell rating(s)	14 Hold rating(s)	13 Buy rating(s)	2 Strong Buy rating(s)	2.48

In the previous week, Amgen had 26 more articles in the media than Bolt Biotherapeutics. MarketBeat recorded 34 mentions for Amgen and 8 mentions for Bolt Biotherapeutics. Amgen's average media sentiment score of 1.06 beat Bolt Biotherapeutics' score of -0.47 indicating that Amgen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bolt Biotherapeutics	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Amgen	23 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	2 Very Negative mention(s)	Positive

Bolt Biotherapeutics has a beta of 1.12, indicating that its share price is 12% more volatile than the broader market. Comparatively, Amgen has a beta of 0.42, indicating that its share price is 58% less volatile than the broader market.

86.7% of Bolt Biotherapeutics shares are held by institutional investors. Comparatively, 76.5% of Amgen shares are held by institutional investors. 9.4% of Bolt Biotherapeutics shares are held by company insiders. Comparatively, 0.9% of Amgen shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Amgen has a net margin of 20.96% compared to Bolt Biotherapeutics' net margin of -455.15%. Amgen's return on equity of 137.41% beat Bolt Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bolt Biotherapeutics	-455.15%	-100.89%	-48.23%
Amgen	20.96%	137.41%	13.28%

Summary

Amgen beats Bolt Biotherapeutics on 13 of the 17 factors compared between the two stocks.

How does Bolt Biotherapeutics compare to Gilead Sciences?

Gilead Sciences (NASDAQ:GILD) and Bolt Biotherapeutics (NASDAQ:BOLT) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, earnings, valuation, risk, profitability and dividends.

Gilead Sciences has a net margin of 30.99% compared to Bolt Biotherapeutics' net margin of -455.15%. Gilead Sciences' return on equity of 48.19% beat Bolt Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gilead Sciences	30.99%	48.19%	18.28%
Bolt Biotherapeutics	-455.15%	-100.89%	-48.23%

Gilead Sciences has higher revenue and earnings than Bolt Biotherapeutics. Bolt Biotherapeutics is trading at a lower price-to-earnings ratio than Gilead Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gilead Sciences	$29.44B	5.41	$8.51B	$7.34	17.49
Bolt Biotherapeutics	$7.70M	1.29	-$33.38M	-$16.33	N/A

Gilead Sciences currently has a consensus price target of $156.93, suggesting a potential upside of 22.21%. Bolt Biotherapeutics has a consensus price target of $34.67, suggesting a potential upside of 567.95%. Given Bolt Biotherapeutics' higher probable upside, analysts clearly believe Bolt Biotherapeutics is more favorable than Gilead Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gilead Sciences	0 Sell rating(s)	3 Hold rating(s)	26 Buy rating(s)	0 Strong Buy rating(s)	2.90
Bolt Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

83.7% of Gilead Sciences shares are held by institutional investors. Comparatively, 86.7% of Bolt Biotherapeutics shares are held by institutional investors. 0.3% of Gilead Sciences shares are held by company insiders. Comparatively, 9.4% of Bolt Biotherapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Gilead Sciences had 38 more articles in the media than Bolt Biotherapeutics. MarketBeat recorded 46 mentions for Gilead Sciences and 8 mentions for Bolt Biotherapeutics. Gilead Sciences' average media sentiment score of 1.41 beat Bolt Biotherapeutics' score of -0.47 indicating that Gilead Sciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Gilead Sciences	36 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive
Bolt Biotherapeutics	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Gilead Sciences has a beta of 0.31, indicating that its stock price is 69% less volatile than the broader market. Comparatively, Bolt Biotherapeutics has a beta of 1.12, indicating that its stock price is 12% more volatile than the broader market.

Summary

Gilead Sciences beats Bolt Biotherapeutics on 12 of the 16 factors compared between the two stocks.

How does Bolt Biotherapeutics compare to Vertex Pharmaceuticals?

Vertex Pharmaceuticals (NASDAQ:VRTX) and Bolt Biotherapeutics (NASDAQ:BOLT) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, risk, earnings, media sentiment, dividends, valuation and profitability.

In the previous week, Vertex Pharmaceuticals had 30 more articles in the media than Bolt Biotherapeutics. MarketBeat recorded 38 mentions for Vertex Pharmaceuticals and 8 mentions for Bolt Biotherapeutics. Vertex Pharmaceuticals' average media sentiment score of 1.19 beat Bolt Biotherapeutics' score of -0.47 indicating that Vertex Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vertex Pharmaceuticals	29 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Bolt Biotherapeutics	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Vertex Pharmaceuticals presently has a consensus target price of $555.91, suggesting a potential upside of 31.33%. Bolt Biotherapeutics has a consensus target price of $34.67, suggesting a potential upside of 567.95%. Given Bolt Biotherapeutics' higher possible upside, analysts plainly believe Bolt Biotherapeutics is more favorable than Vertex Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vertex Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	22 Buy rating(s)	0 Strong Buy rating(s)	2.88
Bolt Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Vertex Pharmaceuticals has higher revenue and earnings than Bolt Biotherapeutics. Bolt Biotherapeutics is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vertex Pharmaceuticals	$12.00B	8.95	$3.95B	$16.86	25.11
Bolt Biotherapeutics	$7.70M	1.29	-$33.38M	-$16.33	N/A

Vertex Pharmaceuticals has a net margin of 35.51% compared to Bolt Biotherapeutics' net margin of -455.15%. Vertex Pharmaceuticals' return on equity of 23.86% beat Bolt Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vertex Pharmaceuticals	35.51%	23.86%	17.13%
Bolt Biotherapeutics	-455.15%	-100.89%	-48.23%

Vertex Pharmaceuticals has a beta of 0.3, indicating that its stock price is 70% less volatile than the broader market. Comparatively, Bolt Biotherapeutics has a beta of 1.12, indicating that its stock price is 12% more volatile than the broader market.

91.0% of Vertex Pharmaceuticals shares are held by institutional investors. Comparatively, 86.7% of Bolt Biotherapeutics shares are held by institutional investors. 0.2% of Vertex Pharmaceuticals shares are held by insiders. Comparatively, 9.4% of Bolt Biotherapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Vertex Pharmaceuticals beats Bolt Biotherapeutics on 13 of the 16 factors compared between the two stocks.

How does Bolt Biotherapeutics compare to Regeneron Pharmaceuticals?

Regeneron Pharmaceuticals (NASDAQ:REGN) and Bolt Biotherapeutics (NASDAQ:BOLT) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, profitability, analyst recommendations, valuation, institutional ownership, media sentiment, dividends and risk.

83.3% of Regeneron Pharmaceuticals shares are owned by institutional investors. Comparatively, 86.7% of Bolt Biotherapeutics shares are owned by institutional investors. 7.0% of Regeneron Pharmaceuticals shares are owned by company insiders. Comparatively, 9.4% of Bolt Biotherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, Regeneron Pharmaceuticals had 19 more articles in the media than Bolt Biotherapeutics. MarketBeat recorded 27 mentions for Regeneron Pharmaceuticals and 8 mentions for Bolt Biotherapeutics. Regeneron Pharmaceuticals' average media sentiment score of 0.68 beat Bolt Biotherapeutics' score of -0.47 indicating that Regeneron Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Regeneron Pharmaceuticals	12 Very Positive mention(s)	3 Positive mention(s)	9 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive
Bolt Biotherapeutics	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Regeneron Pharmaceuticals has a beta of 0.25, suggesting that its stock price is 75% less volatile than the broader market. Comparatively, Bolt Biotherapeutics has a beta of 1.12, suggesting that its stock price is 12% more volatile than the broader market.

Regeneron Pharmaceuticals currently has a consensus price target of $792.65, suggesting a potential upside of 29.14%. Bolt Biotherapeutics has a consensus price target of $34.67, suggesting a potential upside of 567.95%. Given Bolt Biotherapeutics' higher possible upside, analysts clearly believe Bolt Biotherapeutics is more favorable than Regeneron Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Regeneron Pharmaceuticals	0 Sell rating(s)	10 Hold rating(s)	15 Buy rating(s)	2 Strong Buy rating(s)	2.70
Bolt Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Regeneron Pharmaceuticals has a net margin of 29.65% compared to Bolt Biotherapeutics' net margin of -455.15%. Regeneron Pharmaceuticals' return on equity of 13.16% beat Bolt Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Regeneron Pharmaceuticals	29.65%	13.16%	10.17%
Bolt Biotherapeutics	-455.15%	-100.89%	-48.23%

Regeneron Pharmaceuticals has higher revenue and earnings than Bolt Biotherapeutics. Bolt Biotherapeutics is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Regeneron Pharmaceuticals	$14.92B	4.35	$4.50B	$41.04	14.96
Bolt Biotherapeutics	$7.70M	1.29	-$33.38M	-$16.33	N/A

Summary

Regeneron Pharmaceuticals beats Bolt Biotherapeutics on 13 of the 17 factors compared between the two stocks.

Get Bolt Biotherapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BOLT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BOLT vs. The Competition

Export

Metric	Bolt Biotherapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$9.97M	$3.24B	$6.24B	$12.48B
Dividend Yield	N/A	2.33%	2.69%	5.30%
P/E Ratio	-0.32	17.57	21.09	24.35
Price / Sales	1.29	327.12	561.45	126.00
Price / Cash	N/A	116.27	42.31	57.88
Price / Book	0.38	6.53	9.95	6.72
Net Income	-$33.38M	$24.15M	$3.56B	$337.08M
7 Day Performance	-1.70%	-0.28%	-0.07%	1.63%
1 Month Performance	2.57%	3.08%	5.08%	6.29%
1 Year Performance	-14.50%	49.22%	28.39%	35.50%

Bolt Biotherapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BOLT Bolt Biotherapeutics	2.4604 of 5 stars	$5.19 +1.6%	$34.67 +568.0%	-16.4%	$9.97M	$7.70M	N/A	90	Short Interest Increase Analyst Revision
CRIS Curis	2.8181 of 5 stars	$0.49 -1.4%	$17.00 +3,339.9%	-79.4%	$19.54M	$9.44M	N/A	60	Positive News Gap Up
AMGN Amgen	4.3358 of 5 stars	$335.94 -1.0%	$355.19 +5.7%	+13.8%	$183.12B	$36.75B	23.38	31,500	Positive News
GILD Gilead Sciences	4.8875 of 5 stars	$133.73 -0.5%	$156.93 +17.3%	+17.1%	$166.82B	$29.44B	18.22	17,000	Trending News Analyst Upgrade Insider Trade
VRTX Vertex Pharmaceuticals	4.572 of 5 stars	$435.93 +0.3%	$555.17 +27.4%	-4.6%	$110.28B	$12.00B	25.86	6,400	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BOLT) was last updated on 6/3/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Bolt Biotherapeutics (BOLT) Competitors

BOLT vs. CRIS, AMGN, GILD, VRTX, and REGN

How does Bolt Biotherapeutics compare to Curis?

Summary

How does Bolt Biotherapeutics compare to Amgen?

Summary

How does Bolt Biotherapeutics compare to Gilead Sciences?

Summary

How does Bolt Biotherapeutics compare to Vertex Pharmaceuticals?

Summary

How does Bolt Biotherapeutics compare to Regeneron Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BOLT vs. The Competition

Bolt Biotherapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Bolt Biotherapeutics (BOLT) Competitors

BOLT vs. CRIS, AMGN, GILD, VRTX, and REGN

How does Bolt Biotherapeutics compare to Curis?

Do insiders & institutionals believe in BOLT or CRIS?

Which has stronger valuation and earnings, BOLT or CRIS?

Does the media favor BOLT or CRIS?

Which has more risk and volatility, BOLT or CRIS?

Is BOLT or CRIS more profitable?

Do analysts rate BOLT or CRIS?

Summary

How does Bolt Biotherapeutics compare to Amgen?

Which has better earnings & valuation, BOLT or AMGN?

Do analysts rate BOLT or AMGN?

Does the media favor BOLT or AMGN?

Which has more risk & volatility, BOLT or AMGN?

Do institutionals and insiders believe in BOLT or AMGN?

Is BOLT or AMGN more profitable?

Summary

How does Bolt Biotherapeutics compare to Gilead Sciences?

Is GILD or BOLT more profitable?

Which has higher earnings and valuation, GILD or BOLT?

Do analysts rate GILD or BOLT?

Do institutionals & insiders believe in GILD or BOLT?

Does the media favor GILD or BOLT?

Which has more volatility & risk, GILD or BOLT?

Summary

How does Bolt Biotherapeutics compare to Vertex Pharmaceuticals?

Does the media favor VRTX or BOLT?

Do analysts rate VRTX or BOLT?

Which has preferable valuation and earnings, VRTX or BOLT?

Is VRTX or BOLT more profitable?

Which has more risk and volatility, VRTX or BOLT?

Do insiders & institutionals believe in VRTX or BOLT?

Summary

How does Bolt Biotherapeutics compare to Regeneron Pharmaceuticals?

Do institutionals and insiders hold more shares of REGN or BOLT?

Does the media favor REGN or BOLT?

Which has more volatility & risk, REGN or BOLT?

Do analysts rate REGN or BOLT?

Is REGN or BOLT more profitable?

Which has higher earnings & valuation, REGN or BOLT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BOLT vs. The Competition

Bolt Biotherapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools